In Accra last week, Africa CDC Director-General Jean Kaseya addressed African heads of state with a quiet but consequential argument: that the continent's long dependence on external medicines, money, and expertise is not a fixed condition but a choice — and one that growing domestic capacity now makes possible to reverse. Drawing on the $110 million African nations self-financed for the Ebola response, Kaseya outlined a threefold path toward health sovereignty encompassing local pharmaceutical manufacturing, reformed health financing, and control over the data systems that underpin disease su
Africa CDC pushes local pharma manufacturing to boost health sovereignty
Africa should create a market that supports producers within the continent
Mark
Why does Kaseya keep emphasizing that Africa already has manufacturing capacity? Isn't the real barrier just money?
Mimi
Money matters, but it's not the whole story. A manufacturer in Ghana can build pills, but if governments keep buying from European suppliers out of habit or because they have existing contracts, that Ghanaian factory stays small. Kaseya's saying you need to create a market—a reason for governments to buy local.
Mark
So the African Medicines Agency and the procurement mechanism are meant to be that reason?
Mimi
Exactly. They're saying: we'll set standards you have to meet, and if you meet them, we'll buy from you. That's what gives a manufacturer the confidence to borrow money and expand.
Mark
He mentioned losing half of health resources to inefficiencies. That seems like a separate problem from manufacturing.
Mimi
It is, but it's connected. If you're hemorrhaging money through waste, you don't have resources to invest in local capacity. You're stuck asking donors for more. Better management frees up capital that's already there.
Mark
What about the data sovereignty angle? That felt almost like an afterthought in his remarks.
Mimi
It wasn't. He's saying health independence isn't just about pills and money—it's about not being blind when a partner withdraws. If your disease surveillance system runs on servers controlled by someone else, you lose visibility into what's happening in your own country. That's a real vulnerability.
Mark
Is December 2026 a realistic target for having Ebola vaccines and treatments available across the continent?
Mimi
That's aggressive. Clinical trials take time. But he's not saying every African country will have unlimited supply by then—he's saying the continent will have access, meaning the systems and supply chains will be in place. Whether individual countries can afford or distribute them is another question.
The Pulse
- Africa's vulnerability was laid bare when development partners withdrew funding and several countries temporarily lost access to the very health data systems they depended on for disease surveillance — a warning that sovereignty on paper means little without sovereignty in infrastructure.
- The Ebola outbreaks in DRC and Uganda have sharpened the urgency, with travel restrictions, therapeutic shortages, and the race against a December 2026 deadline for continental access to vaccines, treatments, and diagnostics all pressing simultaneously.
- African manufacturers in Algeria, Nigeria, Egypt, and Ghana already have the technical capacity to produce pharmaceuticals, but without guaranteed government procurement they cannot compete against entrenched international suppliers — leaving capability stranded by market structure.
- Africa CDC is moving on multiple fronts at once: clinical trials for Ebola therapeutics are underway, vaccine trials launch next month, the African Medicines Agency is being strengthened, and a continental procurement mechanism is being built to give local producers a predictable customer base.
- Kaseya's most pointed observation may have been the quietest — that nearly half of Africa's health resources are lost to internal inefficiencies, meaning the continent's first act of self-financing could be simply stopping the hemorrhage it already sustains.
In Accra last week, Africa CDC Director-General Jean Kaseya addressed African heads of state with a quiet but consequential argument: that the continent's long dependence on external medicines, money, and expertise is not a fixed condition but a choice — and one that growing domestic capacity now makes possible to reverse. Drawing on the $110 million African nations self-financed for the Ebola response, Kaseya outlined a threefold path toward health sovereignty encompassing local pharmaceutical manufacturing, reformed health financing, and control over the data systems that underpin disease surveillance. The work is unglamorous and institutional, but it marks a meaningful shift in how African leadership is beginning to conceive of health — not as a domain of charitable dependency, but as a strategic pillar of continental self-determination.
Jean Kaseya arrived at the African Union's extraordinary session in Accra last week with an argument stripped of diplomatic softening: Africa has spent long enough waiting for the world to deliver medicines and expertise that the continent is already capable of producing itself.
The Africa CDC director-general pointed to the Ebola response as proof of concept. African nations had collectively mobilized roughly $110 million to support outbreak containment in the Democratic Republic of Congo and Uganda — evidence that domestic financial capacity existed, if governments chose to deploy it. But Kaseya's deeper argument was about structure, not just money. Countries like Algeria, Nigeria, Egypt, and Ghana already possessed pharmaceutical manufacturing capability. The obstacle was market design: local producers had no assurance that African governments would buy from them, leaving them unable to compete against international suppliers with established relationships and deeper resources. Africa CDC's answer was to build a continental procurement mechanism — a guaranteed customer base — alongside a strengthened regulatory framework through the African Medicines Agency, giving local manufacturers the predictability needed to invest and scale.
The Ebola crisis gave the agenda concrete urgency. Kaseya had formally requested the United States lift travel restrictions on Uganda, arguing the response was science-driven. Meanwhile, Africa CDC had already launched Ebola therapeutic trials, with vaccine trials set for the following month and a target of full continental access to vaccines, treatments, and diagnostics by December 2026.
Kaseya also raised two vulnerabilities that rarely surface in diplomatic settings. First, he noted that nearly half of Africa's health resources were being lost to internal inefficiencies — a problem that better financial management alone could substantially address. Second, he pointed to data sovereignty: several African countries had lost access to critical health information systems when external funders withdrew, exposing dangerous gaps in disease surveillance for HIV and other conditions.
The sovereignty Kaseya described was threefold — manufacturing, financing, and data — and none of it required reinventing the wheel. It required building institutional muscle and market incentives. What was new was the framing: African health not as a charity sector sustained by donor goodwill, but as a strategic domain where continental self-sufficiency had become both achievable and necessary.
Jean Kaseya stood before the African Union's assembly in Accra last week with a straightforward argument: Africa has spent long enough waiting for the world to send medicines, money, and expertise when the continent already possesses the capacity to manufacture its own.
The Africa Centres for Disease Control and Prevention director-general was speaking at an extraordinary session of continental heads of state, where the focus had turned to health security, disease preparedness, and the unglamorous work of building systems that don't collapse when external funding dries up. Kaseya's message cut through the diplomatic language: the continent had proven it could respond to crises—Africa CDC had mobilized roughly $110 million from African countries themselves to support the Ebola response in the Democratic Republic of Congo and Uganda, a demonstration that the financial muscle existed domestically if governments chose to deploy it.
But money alone wasn't the point. Kaseya pressed harder on manufacturing. Algeria, Nigeria, Egypt, and Ghana already possessed the technical capacity to produce pharmaceuticals. The problem wasn't capability; it was market structure. African manufacturers had no guarantee that governments would buy from them. They competed against established international suppliers with deep pockets and established relationships. Africa CDC was now working to change that equation by establishing a stronger regulatory framework through the African Medicines Agency and creating a continental procurement mechanism—essentially a guaranteed customer base that would give local producers the predictability they needed to invest and scale.
The Ebola situation underscored the urgency. Kaseya had written to the United States government requesting the removal of travel restrictions on Uganda, arguing that the country's outbreak response was grounded in scientific evidence, not politics. Meanwhile, Africa CDC had already begun clinical trials for Ebola therapeutics and planned to launch vaccine trials the following month, with the goal of ensuring the continent had access to vaccines, treatments, and diagnostic tools by the end of 2026. This wasn't theoretical—it was a concrete timeline.
Yet Kaseya's vision extended beyond medicines. He flagged a hemorrhage in the system that few discussed openly: nearly half of Africa's health resources were being lost to inefficiencies. Better financial management alone could free up enormous sums. More provocatively, he raised the question of data sovereignty. Several African countries had temporarily lost access to critical health information systems when development partners withdrew funding—a vulnerability that had exposed them during disease surveillance work on HIV and other conditions. Africa couldn't claim health independence while remaining dependent on external digital infrastructure that could vanish overnight.
The sovereignty agenda, as Kaseya framed it, was threefold: manufacturing the medicines the continent needed, controlling the money that paid for them, and owning the data systems that tracked disease. None of this was revolutionary. It was the work of building institutional muscle and market incentives. But it represented a shift in how African leadership was thinking about health—not as a charity sector dependent on donor goodwill, but as a strategic domain where continental self-sufficiency was both possible and necessary.
Notable Quotes
The sovereignty agenda is not only about medicines and financing. It is also about owning our health data and building digital systems that remain operational regardless of external support.— Jean Kaseya, Africa CDC Director-General
Want the full story?
Read the original at BusinessGhana ↗
Health & Medicine